Altamira Therapeutics Ltd.
CYTO · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.01 | 0.23 | -0.09 |
| FCF Yield | -801.28% | -265.22% | -77.55% | -51.30% |
| EV / EBITDA | -0.68 | -0.59 | -3.20 | -0.40 |
| Quality | ||||
| ROIC | -85.68% | 3,055.40% | -37.25% | -28.80% |
| Gross Margin | 0.00% | -372.36% | -3,407.33% | 100.00% |
| Cash Conversion Ratio | 0.72 | 2.98 | 0.33 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 20.54% | – | -48.35% |
| Free Cash Flow Growth | -6.33% | 36.31% | -137.45% | 37.27% |
| Safety | ||||
| Net Debt / EBITDA | 0.38 | -0.36 | 0.06 | 1.33 |
| Interest Coverage | 0.00 | -19.76 | -378.50 | -39.09 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 124.01 | 2.67 | 0.00 |
| Cash Conversion Cycle | 0.00 | -217.84 | 3,891.50 | 0.00 |